New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
07:06 EDTNVLS, DYAXDyax and Novellus partner to commercialize Kalbitor in Latin America
Dyax (DYAX) and Novellus (NVLS) announced a strategic partnership for the development and commercialization of Kalbitor (ecallantide) for the treatment of hereditary angioedema and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. Kalbitor is marketed in the U.S. for the treatment of acute attacks of HAE in patients 16 years of age and older. Dyax will receive an upfront payment and is eligible to receive future sales milestones. Dyax is also eligible to receive royalties on net product sales. Novellus is solely responsible for all costs associated with necessary development, regulatory activities, and the commercialization of Kalbitor in the covered territories.
News For DYAX;NVLS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
16:09 EDTDYAXDyax backs FY15 view of KALBITOR net sales $60M-$70M
Dyax has re-iterated its financial guidance for 2015. Revenue guidance includes two components: KALBITOR net sales in the range of $60M-$70M, reflecting the company's expectation that quarterly and annual KALBITOR net sales will fluctuate due to continued volatility in the level of KALBITOR utilization for individual patients. This volatility in utilization rates is due to fluctuations in the number of HAE attacks experienced by patients and the consistency with which patients treat their HAE attacks with KALBITOR; Development and license fees in the range of $7M-$9M. These fees exclude all potential royalties which would be earned from licensees' sales of LFRP product.
16:08 EDTDYAXDyax reports Q1 EPS (5c), consensus (5c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use